PMID- 34597309
OWN - NLM
STAT- MEDLINE
DCOM- 20211129
LR  - 20211129
IS  - 1932-6203 (Electronic)
IS  - 1932-6203 (Linking)
VI  - 16
IP  - 10
DP  - 2021
TI  - Diabetic macular edema: Safe and effective treatment with intravitreal 
      triamcinolone acetonide (Taioftal).
PG  - e0257695
LID - 10.1371/journal.pone.0257695 [doi]
LID - e0257695
AB  - PURPOSE: To suggest the safety and efficacy of preservative-free triamcinolone 
      acetonide intravitreal injectable suspension (Taioftal) for the treatment of 
      diabetic macular edema. METHODS: A prospective clinical study involved 49 
      patients (49 eyes), that were treated with Taioftal and followed-up for six 
      months. Complete ophthalmic examination, including spectral domain optical 
      coherence tomography, was performed at baseline, and at month 1, 3, 6 after the 
      intravitreal injection. Accurate collection and analysis of best-corrected visual 
      acuity (BCVA), central foveal thickness (CFT), intraocular pressure (IOP), and 
      adverse events (AEs) were carried out in order to evaluate visual function and 
      macular morphology before and after treatment. RESULTS: Median BCVA value chosen 
      as comparing statistics was significantly improved at every follow-up time points 
      (gain of 6 letters at month 1, 12 at month 3 -improvement up to 24% at month 3 
      with stabilization until month 6) compared to baseline, as certified by 
      Kruskal-Wallis rank sum test (P<0.05). Median CFT significantly waned at each 
      follow-up times (decrease of about 65 mum at month 1, 155 at month 3 -reduction up 
      to 28% at month 3 keeping good outcome until month 6) compared to baseline 
      (P<0.05). IOP elevation, with no severe increases, was the most common among 
      spotted AEs (median of 23 mmHg at month 1, 20 at month 3). CONCLUSION: 
      Intravitreal injection of preservative-free triamcinolone (Taioftal) is an 
      effective, safe and inexpensive drug used to improve visual acuity and reduce 
      central foveal thickness in eyes affected by diabetic macular edema during an 
      average time of 6 months. Temporary, never severe, elevation of IOP is totally 
      manageable with topical medications. No serious vision-threatening complications 
      are related to the use of intravitreal triamcinolone injections.
FAU - Sorrentino, Francesco Saverio
AU  - Sorrentino FS
AUID- ORCID: 0000-0002-7691-8980
AD  - Department of Surgical Sciences, Unit of Ophthalmology, Ospedale Maggiore, 
      Bologna, Italy.
FAU - Bonifazzi, Claudio
AU  - Bonifazzi C
AD  - Department of Biomedical Sciences, University of Ferrara, Ferrara, Italy.
FAU - Parmeggiani, Francesco
AU  - Parmeggiani F
AUID- ORCID: 0000-0002-9296-0986
AD  - Division of Ophthalmology, Department of Biomedical and Surgical Sciences, 
      University of Ferrara, Ferrara, Italy.
LA  - eng
PT  - Clinical Study
PT  - Journal Article
DEP - 20211001
PL  - United States
TA  - PLoS One
JT  - PloS one
JID - 101285081
RN  - 1ZK20VI6TY (Triamcinolone)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Diabetic Retinopathy/*drug therapy
MH  - Female
MH  - Humans
MH  - Intravitreal Injections
MH  - Italy
MH  - Macular Edema/*drug therapy
MH  - Male
MH  - Middle Aged
MH  - Prospective Studies
MH  - Treatment Outcome
MH  - Triamcinolone/*administration & dosage
PMC - PMC8486126
COIS- The author has declared that no competing interests exist.
EDAT- 2021/10/02 06:00
MHDA- 2021/11/30 06:00
PMCR- 2021/10/01
CRDT- 2021/10/01 17:16
PHST- 2021/05/28 00:00 [received]
PHST- 2021/09/07 00:00 [accepted]
PHST- 2021/10/01 17:16 [entrez]
PHST- 2021/10/02 06:00 [pubmed]
PHST- 2021/11/30 06:00 [medline]
PHST- 2021/10/01 00:00 [pmc-release]
AID - PONE-D-21-17143 [pii]
AID - 10.1371/journal.pone.0257695 [doi]
PST - epublish
SO  - PLoS One. 2021 Oct 1;16(10):e0257695. doi: 10.1371/journal.pone.0257695. 
      eCollection 2021.